Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.46 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 12/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6079727 | 0.85 | ADORA2A (0.48) | KDM4EPDE10AADORA2AALDH1A1HPGD | |
| SCHEMBL6080957 | 0.82 | PDE10A (0.52) | KDM4EPDE10AADORA2AALDH1A1HPGD | |
| SCHEMBL6080920 | 0.77 | PDE10A (0.50) | KDM4EPDE10AADORA2AALDH1A1HPGD | |
| SCHEMBL6081023 | 0.76 | KDM4E (0.52) | KDM4EPDE10AADORA2AALDH1A1HPGD | |
| SCHEMBL6592578 | 0.75 | HPGDS (0.47) | KDM4EPDE10AADORA2AALDH1A1HPGD | |
| SCHEMBL6081016 | 0.73 | PDE10A (0.56) | KDM4EPDE10AADORA2AALDH1A1HPGD | |
| SCHEMBL6080975 | 0.70 | TNKS (0.51) | KDM4EPDE10AALDH1A1HPGDMEN1 | |
| SCHEMBL17966023 | 0.70 | ADORA2A (0.61) | ADORA2A | |
| SCHEMBL6079920 | 0.68 | HPGDS (0.47) | KDM4EPDE10AALDH1A1HPGDLMNA | |
| SCHEMBL6080248 | 0.68 | HPGDS (0.47) | KDM4EPDE10AADORA2AALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060183909-A1 | Compositions derived from quinoline and quinoxaline, preparation and use thereof | NEURO3D (FR) | 2006-08-17 | — | — | US | claimed |
| US-20060183909-A1 | Compositions derived from quinoline and quinoxaline, preparation and use thereof | NEURO3D (FR) | 2006-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060183909-A1 | Compositions derived from quinoline and quinoxaline, preparation and use thereof | NQO1, NQO2, RECQL | KDM4E 1006/4885PDE10A 702/4885ADORA2A 1442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.